LABA/LAMA combination, exercise and lung hyperinflation in COPD: a meta-analysis

M. Cazzola (Roma, Rm, Italy)

Source: International Congress 2017 – COPD management
Session: COPD management
Session type: Thematic Poster
Number: 683
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Cazzola (Roma, Rm, Italy). LABA/LAMA combination, exercise and lung hyperinflation in COPD: a meta-analysis. 683

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 33s
Year: 2006

Metronome-paced hyperventilation, CT measurements and exercise to investigate dynamic hyperinflation contrasting tiotropium versus indacaterol treatment in moderate COPD patients
Source: International Congress 2015 – Unravelling the mechanisms of symptoms and exercise limitationas in disease
Year: 2015


Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


A systematic review and meta-analysis of the effect of dual versus mono- long-acting bronchodilator therapy on exercise endurance in COPD
Source: International Congress 2016 – Latest insights into functional capacity and muscle weakness in chronic lung diseases
Year: 2016

The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Pre-exercise inhalation of short-acting ß-agonists (SABA) safely improves exercise performance in severe COPD patients by reducing lung hyperinflation
Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Year: 2010

Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: Two randomised clinical trials
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013


Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
Source: Eur Respir J 2004; 23: 832-840
Year: 2004



LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
Source: Eur Respir Rev 2017; 26: 160043
Year: 2017



First dose response to tiotropium in COPD: Impact on dyspnea, lung hyperinflation and distal airways
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013


Pooled analysis of 24-h lung function following treatment with the LAMA/LABA glycopyrronium/formoterol fumarate fixed-dose combination, delivered by a novel MDI co-suspension technology (GFF MDI), in COPD patients (pts)
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016


QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015

Lung hyperinflation in COPD: the impact of pharmacotherapy
Source: Eur Respir Rev 2006; 15: 85-89
Year: 2006



Mechanisms limiting exercise in COPD: new insights
Source: Annual Congress 2005 - Mechanical factors limiting physical exercise in disease
Year: 2005

Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD
Source: Annual Congress 2006 - COPD therapy
Year: 2006


Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013

Effect of breathing parameters on lung dose in case of two combination drugs used in asthma and COPD therapy
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016


Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015